Welcome to GlycoMatters Biotech
Opening New Roads for Precision Oncology
Welcome to GlycoMatters Biotech
Opening New Roads for Precision Oncology
Strategic vision
Strategic vision
Strategic vision
Cancer management remains challenged by the lack of cancer-specific signatures for precise detection, patient stratification and comprehensive design of targeted therapeutics. GlycoMatters is strongly committed to generating effective solutions for the oncology market, with high transformational impact for patient care.
GlycoMatters value proposition builds on exploiting distinctive “cancer signatures” generated by simultaneous alterations in both glycans and proteins occurring at the cell surface. The unique specificity provided by such glycoprotein signatures sets a new generation of biomarkers and immune epitopes for the design of innovative molecular constructs and the application of effective glyco-inspired cancer vaccines.
Technology
Strategic vision
Strategic vision
Glycomatters R&D pipeline addresses the oncology market challenges and patients' expectations with a dedicated biomarker discovery platform capable of identifying cancer specific signatures and translating clinically relevant targets into innovative, effective and safer immunotherapies.
It builds on cutting-edge glycoproteogenomics and data mining strategies for the identification of key alterations in protein glycosylation that precisely portrait cancer progression and dissemination.
GlycoMatters R&D pipeline also covers the translation of relevant molecular information into improved cancer immunotherapies.
Critical know-how in nanomedicine is dedicated to develop glyco-inspired vaccines able to unleash the unmet potential of the immune system to eliminate cancer cells and avoid relapse.
Innovative vision for science-enabled technologies
GlycoNeoantigens Discovery
GlycoMatters uses cutting-edge oncoproteogenomicsapproaches combining genomics and glycomics customized databases to comprehensively interrogate large proteomics datasets for cancer neoantigens. This has allowed access to deeper layers of unforeseen molecular information, overlooked by conventional proteomics. The company has expanded this concept to include alterations in protein glycosylation occurring at the cell surface of cancer cells, which has decisively improved molecular subtyping and provided targetable functional nodes, setting a new generation of cancer biomarkers.
GlycoNeoantigen-based Cancer Immunotherapy
GlycoMatters ambition extends beyond biomarker discovery, towards the translation of cancer neoantigens into effective and safer cancer immunotherapies. Recent advances in nanomedicine are brought together with innovative glyco-inspired nano designs, specifically tailored to unleash the full capacity of the immune system against cancer cells with minimal side-effects ,while providing effective protection against relapse.
The Team
José Alexandre Ferreira, PhD, Co-founder and CEO
José Alexandre Ferreira, PhD, Co-founder and CEO
José Alexandre Ferreira, PhD, Co-founder and CEO
José Alexandre Ferreira is an assistant researcher and team leader at the Portuguese Oncology Institute of Porto (IPO-Porto) in Portugal, where he works in close collaboration with clinicians and cancer scientists around the world to bring improvements to patient care. He has specialized in cancer glycoproteomics for precision oncology and established a solid framework for graduate training in this context.
Lúcio Lara Santos, MD, PhD Co-founder
José Alexandre Ferreira, PhD, Co-founder and CEO
José Alexandre Ferreira, PhD, Co-founder and CEO
Lucio Santos is a senior surgeon, Professor of Surgical Oncology, former director of the Digestive Pathology Unit, currently the coordinator of the Experimental Pathology and Therapeutics Group, member of the Surgical Oncology Department and Head of the Intermediate Care Unit at The Portuguese Oncology Institute. He also serves as Adviser of Oncology for ONCOCIR - Education and Care in Oncology, Angola. He conducts basic, translational and clinical research in experimental pathology and oncology, including gastrointestinal, breast cancer, and cancers related to infections foreseeing precision oncology.
Rafael Costa, PhD and Co-founder
Rafael Costa, PhD and Co-founder
Rafael Costa, PhD and Co-founder
R. Costa is currently an assistant researcher at FCT-NOVA and a collaborator at Center of Intelligent Systems, IST-UL. He is also an invited assistant professor. His research focuses on systems biology modeling and data science with application in biotechnology and health.
André Silva, PhD and Co-founder
Rafael Costa, PhD and Co-founder
Rafael Costa, PhD and Co-founder
A. Silva is an assistant researcher at LAQV, University of Porto. He is an invited assistant professor at the Faculty of Sciences (FCUP) and Instituto de Ciências Biomédicas Abel Salazar (ICBAS-UP). He is a specialist in bioanalytical chemistry, with focus on proteomics and mass spectrometry.